CareDx (CDNA) Tops Q3 EPS by 41c, provides guidance

CareDx (NASDAQ: CDNA) reported Q3 EPS of ($0.18), $0.41 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $67.2 million versus the consensus estimate of $53.14 million.

Guidance:

For the full year 2023, CareDx expects revenue to be in the range of $274 to $278 million, versus the consensus of $255.4 million.

For earnings history and earnings-related data on CareDx (CDNA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral